Cancer Control最新文献

{"title":"Immunotherapy Landscape for Acute Lymphoblastic Leukaemia (ALL) in Malaysia: A Qualitative Study Among Healthcare Professionals From Two National Referral Centres.","authors":"Mei Pin Ngu, Noorasyikin Shamsuddin, Hasniza Zaman Huri, Wei Lim Chong, Izyan A Wahab","doi":"10.1177/10732748261476852","DOIUrl":"10.1177/10732748261476852","url":null,"abstract":"<p><p>IntroductionRelapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) carries a poor prognosis in adults. Although immunotherapies have expanded treatment options, access to these life-extending therapies remains a challenge in many resource-constrained healthcare systems. This study explored healthcare professionals' perspectives on the immunotherapy landscape for adult B-ALL in Malaysia's public sector.MethodsA qualitative study was conducted using in-depth, semi-structured interviews with 11 healthcare professionals from two tertiary centres in Malaysia. Interviews were audio-recorded, transcribed verbatim, and analysed using thematic analysis.ResultsSix themes characterised the current implementation landscape. While the clinical benefits of immunotherapy were widely recognised, its use remained largely restricted to salvage or bridging therapy. Financial constraints, fragmented funding mechanisms, administrative burden, infrastructure constraints, limited clinical expertise or experience, and the absence of standardised treatment pathways hindered wider integration into routine care. These collectively contributed to inequitable access and delayed treatment initiation in a setting of a rapidly progressive disease.ConclusionsHealthcare professionals recognise the therapeutic value of immunotherapy for adult B-ALL, but its implementation in Malaysia's public sector remains selective and constrained. Systemic reforms across funding, formulary policy, workforce development, and clinical governance may be needed to close the gap between therapeutic potential and patient outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261476852"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian Burden of Liver Cancer 1990-2021 and Predictions to 2040: An Analysis of the Global Burden of Disease Study 2021.","authors":"Liandong Chen, Weibo Zheng, Haojie Ying, Xinyue Chen, Han Yan, Binzhe Zhou, Yuyuan Sun, Qihui Shao, Hanyu Xu, Bowen Jin, Haonan Jin, Bin Fu","doi":"10.1177/10732748261446367","DOIUrl":"10.1177/10732748261446367","url":null,"abstract":"<p><p>BackgroundLiver cancer (LivCa) is one of the most prevalent malignancies globally, and can result from viral hepatitis, non-alcoholic steatohepatitis (NASH), and alcohol use. LivCa is of increasing concern in Asia, but the burden of etiology-specific LivCa and future projections remain to be elucidated.MethodsWe extracted the incidence, mortality, and disability-adjusted life years (DALYs) of LivCa across Asia and in 34 Asian countries in 1990-2021 from the Global Burden of Disease Study 2021 (GBD 2021). We then calculated their estimated annual percentage change (EAPC) and percentage variation to quantify the changes in the burden of LivCa. The association of the level of social development with LivCa burden was explored using the sociodemographic index (SDI). Moreover, the trend of the epidemiology of LivCa burden in Asia from 2022 to 2040 was predicted using the Bayesian age-period-cohort (BAPC) model.ResultsOverall, the age-standardized incidence, mortality, and DALYs rates of LivCa in Asia showed a general declining trend, with EAPCs of -0.47, -0.73, and -1.14, respectively. Notably, hepatitis B virus remained the predominant cause. However, the burdens attributed to non-alcoholic steatohepatitis and alcohol use increased significantly, while that of hepatoblastoma decreased. Regarding demographic distribution, the highest disease burden was observed among males and the elderly population aged 85-94 years. Geographically, Nepal, Taiwan (Province of China), India, and Malaysia contributed most substantially to the increasing burden. In terms of risk factors, high BMI and alcohol use were prominent in Central Asia, whereas smoking was a key factor in East and Southeast Asia. Additionally, a positive correlation was observed between the SDI and the burden of LivCa. Finally, projections from the BAPC model indicated a persistent decline in the burden of LivCa from 2022 to 2040.ConclusionsDespite the overall decreasing trend, targeted strategies addressing etiology-specific risks and regional disparities are urgently needed to further reduce the future burden of LivCa in Asia.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261446367"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"It Was Part of the Plan, so I Showed up\": An Exploration of Patient Experiences With an Embedded Exercise Referral Process During Cancer Treatment.","authors":"Mary A Kennedy, Jack Dalla Via, Kim Edmunds, Pam Eldridge, Yvonne Zissiadis, Lauren Fortington","doi":"10.1177/10732748261451084","DOIUrl":"10.1177/10732748261451084","url":null,"abstract":"<p><p>IntroductionExercise is a key part of cancer care, yet its integration into routine practice remains limited. This study explored the experiences of people living with and beyond cancer, with an updated, opt-out referral model embedded within a supportive oncology setting, focusing on initial engagement with exercise physiology appointments. Through this model, patients were automatically scheduled for a consultation with an in-house exercise professional during their cancer treatment.MethodsA qualitative descriptive design comprised of two focus groups with 13 participants was employed to explore views across pre-defined elements of the model: referral to exercise, appointments, counselling, and tailoring.ResultsParticipants valued the automatic appointment structure as it normalised exercise as being part of their treatment and reduced the burden from decision-making and arrangement of appointments. Trust in their treating doctors and nurses, together with consistent messaging, reinforced exercise as a medically endorsed intervention. Counselling on exercise addressed misinformation, highlighted the physiological rationale, and helped foster a sense of control and agency. The inclusive gym environment and tailored plans further supported engagement with exercise, from which the importance of collaborative but individualised care was noted. While the opt-out process facilitated initial uptake, sustained access to exercise services beyond the clinical setting remains a challenge.ConclusionsFindings support the feasibility and acceptability of integrated referral pathways and underscore the need for system-level changes and community partnerships to ensure long-term, equitable access to exercise in cancer care.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261451084"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147876355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Home-Based Exercise With Telehealth Guidance in Lymphoma Survivors Entering Cardio-Oncology Rehabilitation: A Randomized Controlled Trial.","authors":"Katerina Chamradova, Ladislav Batalik, Petr Winnige, Filip Dosbaba, Martin Hartman, Marian Felsoci, Garyfallia Pepera, Jing Su","doi":"10.1177/10732748261455980","DOIUrl":"10.1177/10732748261455980","url":null,"abstract":"<p><p>IntroductionLymphoma survivors are at increased cardiovascular risk due to cardiotoxic therapies and commonly experience reduced cardiorespiratory fitness and quality of life. Telehealth-supported home-based exercise (HBE) may extend access to cardio-oncology rehabilitation (CORE); however, evidence from randomized trials in lymphoma survivors remains limited. This trial compared the short-term effects of telehealth-supported HBE versus center-based exercise (CBE) in lymphoma survivors entering CORE.Materials and MethodsIn this single-center, single-blind, parallel-group randomized controlled trial, lymphoma survivors in remission were randomized 1:1 to a 12-week telehealth-supported HBE program or supervised CBE. The primary endpoint was cardiorespiratory fitness, operationalized as peak oxygen uptake (pVO₂, mL·kg^-1·min^-1) assessed by cardiopulmonary exercise testing (CPET) at 12 weeks. Key secondary outcomes were maximal workload (W) and SF-36 Physical Functioning. Between-group effects were estimated using ANCOVA with baseline adjustment (intention-to-treat; missing outcomes handled by multiple imputation).ResultsEighty participants were randomized (HBE n=40; CBE n=40); post-intervention CPET outcomes were available for 69 participants (HBE n=34; CBE n=35). pVO₂ improved in both groups, with no significant baseline-adjusted between-group difference at 12 weeks (adjusted mean difference HBE-CBE -0.60 mL·kg^-1·min^-1, 95% CI -2.38 to 1.17; p=0.504). No between-group differences were observed for maximal workload (2.05 W, 95% CI -9.20 to 13.30; p=0.721) or SF-36 Physical Functioning (1.69 points, 95% CI -3.37 to 6.74; p=0.512). Adherence was high in both groups (HBE 80.1% vs CBE 77.9%). No adverse events were reported. Costs per participant were CZK 13,032 for HBE versus CZK 24,900 for CBE (48% lower for HBE).ConclusionTelehealth-supported HBE achieved comparable short-term improvements in exercise capacity and physical functioning to supervised CBE among lymphoma survivors entering CORE, with high adherence, no reported adverse events, and substantially lower provider costs. Telehealth-guided HBE represents a pragmatic, lower-cost delivery option to expand access to CORE.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261455980"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148303672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.","authors":"Ali Kaan Güren, Nazım Can Demircan, Murat Sarı, Osman Köstek, İbrahim Vedat Bayoğlu","doi":"10.1177/10732748261451083","DOIUrl":"10.1177/10732748261451083","url":null,"abstract":"<p><p>IntroductionTrastuzumab deruxtecan (T-DXd)-induced interstitial lung disease/pneumonitis (ILD) represents a clinically significant and potentially fatal toxicity. Discrepancies exist regarding its reported frequency and severity between clinical trials (CTs) and real-world data (RWD). This meta-analysis aims to evaluate the incidence of T-DXd-related ILD and investigate its differences between CTs and RWD.MethodsA systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Databases were searched from their inception through January 2026. CTs and real-world studies reporting T-DXd-related ILD were included in the analysis. Pooled incidences for all-grade, grade ≥3, and fatal ILD were calculated using random-effects models. Subgroup analyses comparing CTs and RWD, and meta-regression analyses for relevant outcomes were performed.ResultsThirty-five studies (19 CTs, 16 RWD) including 6840 patients were analyzed. The pooled incidence was 8.8% for all-grade ILD, 1.6% for grade ≥3 ILD, and 0.26% for fatal ILD. RWD was independently associated with lower reported rates of all-grade and fatal ILD, while prior lines of therapy were the main predictor of grade ≥3 ILD.ConclusionILD risk with T-DXd differs by severity and data source. Vigilant monitoring is essential, particularly in heavily pretreated patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261451083"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147857493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Early-Onset Gastrointestinal Cancers Among Core Labor Force From 1990 to 2021: Insights From the Global Burden of Disease Study 2021.","authors":"Yi-Meng Ren, Zi-Er Fan, Xin-Yang Liu, Quan-Lin Li, Ping-Hong Zhou","doi":"10.1177/10732748261460115","DOIUrl":"10.1177/10732748261460115","url":null,"abstract":"<p><p>IntroductionThe global status of core labor force (CLF) health is underestimated, particularly the burden of patients with early-onset gastrointestinal cancers (EOGICs), aged 15-49 years old. We aim to investigate the pattern and trend of EOGICs among CLF from 1990 to 2021.MethodsEOGIC burden and its attributable risk factors were estimated using data from the GBD 2021. The ASR and EAPC by age, sex and SDI were utilized for measuring incidence rate trends. Joinpoint regression analysis was utilized to explore the variation in disease burden. The Bayesian Age-Period-Cohort (BAPC) model was performed to forecast the disease burden up to 2050.ResultsFrom 1990 to 2021, the global ASIR for EOGICs among core labor force remained broadly stable, moving from 10.9 to 9.62 per 100,000(EAPC=-0.42, -1.70 to 0.87), while incident cases increased from 295,514 to 379,709. The overall incidence pattern was driven largely by declines in early-onset GC. The age-standardized DALY rate declined from 375.16 to 238.40 per 100,000(EAPC=-1.46, -2.76 to -0.15). Only early-onset CRC showed increasing DALYs. Joinpoint analysis showed a continuous downward trend in the ASIR for overall EOGICs(AAPC=-0.97%; -0.81 to -1.08). Risk-factor decomposition indicated substantial contributions from modifiable exposures, mainly led by smoking, alcohol use, and dietary risks, with marked sex- and age-specific variation.ConclusionThe results of the present study are significant for global health policy and practice in core labor force. Differentiated intervention and outreach strategies based on age and gender would be necessary to reduce the impact of EOGICs.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261460115"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13269990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148254219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Qualitative Analysis of Factors Contributing to Cervical Cancer Screening Implementation in Health Care Facilities in Uganda.","authors":"Laura M Bogart, Laura Whitaker, Violet Gwokyalya, Jolly Beyeza-Kashesya, Joseph K B Matovu, Sylvia Nakami, Eve Namisango, George Timmins, Allison J Ober, Temusa Rukundo-Ayeh, Harold D Green, Rhoda K Wanyenze, Glenn J Wagner","doi":"10.1177/10732748261450722","DOIUrl":"10.1177/10732748261450722","url":null,"abstract":"<p><p>IntroductionCervical cancer prevalence and incidence are high in sub-Saharan Africa, especially in Uganda, where screening rates are low, despite government policy recommending screening for all women aged 25-49 every three years. Most prior research focuses on client-related barriers to screening, including women's fears about the screening procedure, lack of partner support, and community-level stigma. Fewer studies elaborate on inner context factors related to health care systems, facilities, and providers. The aim of this study was to use qualitative methods to explore inner context factors that may affect cervical cancer screening in Uganda.MethodsWe recruited 20 health care facility administrators, 6 providers of cervical cancer screening, 2 district health officers, 2 division medical officers, and one government health official for key informant interviews, and 69 women (31 screened and 38 not screened for cervical cancer) for focus group discussions. Participants were recruited from four health care facilities that varied by urbanicity and funding source: one urban public facility, one urban private non-profit facility, one rural public facility, and one rural private non-profit facility.ResultsInner context themes emerged around infrastructure needs (insufficient space, equipment, and supplies) and staffing issues (inadequate staff quantity and training), which contributed to lower quality of care (e.g., long wait-times; painful, rushed exams). Women described privacy concerns as well as discomfort with male and young providers. Women with HIV were prioritized for screening based on funding streams and inability to serve all women given infrastructure and staffing issues. Despite barriers, many stakeholders were committed to providing cervical cancer screening services, and many women saw the value of screening.ConclusionThis study identified inner context barriers related to resource shortfalls, which affected quality of care. Low cost solutions are needed to improve health care readiness and increase reach of cervical cancer screening in Uganda.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261450722"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13230671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148151986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing and Interpreting a Machine Learning Model for Identifying Liver Metastasis in Gastric Cancer.","authors":"Peng Song, Ziang Chen, Wencong Tian, Jia Zhao, Yanhong Liu, Chuntao Wang, Hong Fang, Hongzhi Wang, Na Li, Yongjie Zhao, Lei Cao","doi":"10.1177/10732748261454462","DOIUrl":"10.1177/10732748261454462","url":null,"abstract":"<p><p>IntroductionLiver metastasis (LM) is the most common site of distant metastasis in gastric cancer (GC), significantly affecting patient prognosis. This study developed a machine learning (ML) model to predict the risk of liver metastasis in gastric cancer patients using data from the Surveillance, Epidemiology, and End Results (SEER) database.MethodsData from eligible GC patients between 2010 and 2015 were collected from the SEER database. Stratified randomization divided the data into a training set (70%, n=7671) and a validation set (30%, n=3287). Univariate and multivariate logistic regression analyses, along with Boruta-Shap algorithm and Least Absolute Shrinkage and Selection Operator (LASSO) for feature selection, were performed. Seven ML algorithms were developed to predict the risk of liver metastasis in gastric cancer patients. Receiver Operating Characteristic (ROC) curve analysis, including Area Under the Curve (AUC), sensitivity, specificity, and Negative Predictive Value (NPV), was used to assess performance. The SHapley Additive Explanations (SHAP) framework identified key predictors for liver metastasis.ResultsA total of 10,958 GC patients were enrolled, among whom 766 (6.99%) presented synchronous LM. After screening, gender, T stage, tumor size, surgery, radiation therapy, lung metastasis, and bone metastasis were identified as key influencing factors for liver metastasis in gastric cancer. The eXtreme Gradient Boosting (XGB) model exhibited superior performance with an AUC of 0.846 (95% CI: 0.820-0.872) and an NPV of 97.7%. Decision Curve Analysis (DCA) and calibration curve analyses confirmed its reliable clinical utility and predictive accuracy. Furthermore, the SHAP framework revealed that surgery, radiation therapy, and T stage were the primary factors influencing the model's predictions.ConclusionsThis study developed and validated a predictive XGB model using clinical and pathological data to predict the risk of LM in GC patients. The model can provide critical support for the development of personalized medical strategies in clinical practice.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261454462"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers and Facilitators of Programmatic HPV Testing: Lessons Learnt From Two In-Depth Provincial Case Studies Ten Years After the Jujuy Demonstration Project in Argentina.","authors":"Melisa Paolino, Partha Basu, Eric Lucas, Mauricio Cucchiaro, Evangelina Melnik, Mariela Nieva, Natalia Martiarena, Marcelo Ríos, Rosa Laudi, Silvina Arrossi","doi":"10.1177/10732748261446046","DOIUrl":"10.1177/10732748261446046","url":null,"abstract":"<p><p>IntroductionAchieving the global goal of cervical cancer elimination faces major challenges, particularly in ensuring the large-scale and sustained implementation of proven technologies. In Argentina, HPV testing as primary screening was introduced through the Jujuy Demonstration Project (JDP) in 2012. The aim of this study is to analyze barriers and facilitators of the implementation of HPV testing in two provinces-Jujuy, and Catamarca-a decade after the JDP's completion.MethodsWe carried out a descriptive in-depth case study using a mixed-method approach, using qualitative and quantitative methods. Data were collected through participant observations in health services, semi-structured interviews with key informants, analysis of secondary sources, and program indicators. Barriers and facilitators were analyzed using an adapted Health System Framework focusing on four key dimensions: stewardship, organizational capacity, financing, and technology.ResultsRegarding stewardship, reduced technical support and monitoring from the National Program emerged as significant barrier. About financing, the most critical obstacle was the national interruption in the provision of HPV tests. Although both provinces have initiated procedures to purchase tests using provincial funds, this process was constrained by limited financial resources and competing priorities. Finally, regarding organizational capacity, challenges persisted in maintaining laboratory centralization, sustaining the offer of self-collection, and fully utilizing information systems for program monitoring. Facilitators related to stewardship included the stability of human resource in both provinces and the long-standing institutional recognition and leadership of provincial program staff. Sustained adherence to national guidelines and the existence of provincial resolutions were key enablers of continuity. In addition, acceptability of the technology remained high, with HPV testing continuing to be widely accepted in both provinces.ConclusionsOur findings reveal barriers and facilitators in the implementation ten years after JDP finalization, providing valuable lessons for scaling up HPV-based screening in national cancer control programs.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261446046"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Insight into who you are as a human being\": Perceptions of the Utility and Usability of a Values Assessment Tool (VAsT) for Women With Metastatic Breast Cancer.","authors":"Robert Crowder, Victoria Crowder, Soroush Fariman, Natasha Joglekar, Danielle Anderson, Juanita Miller, Stephanie Walker, Emily M Ray, Shaunta Ford-Pierce, Bryce B Reeve, Antonia Bennett, Melissa Mazor, Allison M Deal, Lorinda A Coombs","doi":"10.1177/10732748261466394","DOIUrl":"10.1177/10732748261466394","url":null,"abstract":"<p><p>IntroductionWomen with metastatic breast cancer (mBC) often face complex treatment decisions that require careful consideration of values and priorities, which may be unique to each individual and evolve over the course of treatment. The patient-reported Values Assessment Tool (VAsT) was developed to help prioritize and communicate values to clinicians and care partners, thereby improving treatment decision-making. This study aimed to further refine the VAsT, assess perspectives on utility and usability of the VAsT, and evaluate the potential impact on communication between women with mBC, care partners, and clinicians who utilize the VAsT.MethodsA qualitative study using cognitive interview methodology was conducted. Qualitative cognitive interviews were conducted with seven women with mBC, three care partners, and four breast oncology clinicians. Participant feedback informed the refinement of the tool, and thematic analysis guided by Normalization Process Theory was conducted to understand the utility and usability of the VAsT among women with their clinicians and care partners.ResultsThe VAsT domains were confirmed (e.g., <i>financial concerns of affording cancer care; minimize and manage side effects of treatment</i>), and instructions and purpose were refined. Three themes related to the usability and communication with VAsT were identified: 1) Comprehension of values and meaningful use of the tool, 2) Usability and format of the VAsT, and 3) Communication and clinical utility of the VAsT.ConclusionFindings indicate there is variation in perspectives of how often the VAsT should be utilized over the course of treatment, which future research on the feasibility and efficacy of the VAsT will better elucidate. Women with mBC may use the VAsT to facilitate communication and build trust with clinicians, which is perceived to allow for higher-quality care and value-congruent treatment decisions.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261466394"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13420118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}